Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi-Aventis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Sanofi-Aventis

Generics hurt pharma revenues in U.S.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-Aventis 3Q10

3Q Revenues: $10.0 billion (-5%)

3Q Earnings: $3.2 billion (+5%)

YTD Revenues: $30.2 billion (+1%)

YTD Earnings: $9.7 billion (+5%)

Comments: Pharma sales dropped 4% for the quarter to $8.5 billion, due in part to generic Lovenox and Eloxatin in the U.S., and generic Plavix in Europe. YTD pharma sales were down 1% to $26.4 billion. Lovenox sales dropped 26% to $760 in 3Q10, with a 47% drop in U.S. sales and a 5% increase in non-U.S. markets. Vaccine revenues rose 9% in the quarter to $1.6 billion and are up 18% YTD to $3.8 billion. Pharma sales (not including diabetes products) in emerging markets were up 13% and 21% for the quarter and YTD, respectively, to $3.0 billion and $9.0 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters